Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), has priced its initial public offering (IPO) filing to the Hong Kong Stock Exchange at a range of HKD 60.6 to 72.8 per share. At an assumed offering price of HKD 60.60 per share, Kelun-Biotech anticipates raising HKD 1.38 billion (USD 176 million) in net proceeds after accounting for commissions and other expenses.
Funds Allocation for Pipeline Development and Expansion
The proceeds from the IPO are designated for the research and development of Kelun-Biotech’s core pipeline products, including SKB264, an antibody drug conjugate (ADC) in the Phase III stage, and A166, a HER2 ADC at the New Drug Application (NDA) filing stage. Additionally, the funds will be invested in the company’s ADC, macromolecule, and small-molecule technology platforms, as well as the expansion of manufacturing capacity and enhancement of quality control systems.
Focus on Oncology, Autoimmune, and Metabolic Diseases
Founded in 2016, Kelun-Biotech specializes in oncology, autoimmune diseases, and metabolic diseases. The company currently has 14 drug candidates in clinical stages. Notably, it has entered into three licensing agreements with US pharmaceutical major Merck, Sharp & Dohme (MSD), involving 9 of the firm’s pipeline ADCs and valued at up to USD 11.8 billion in aggregate.
Financial Performance and Partnership with MSD
In 2022, Kelun-Biotech reported revenues of RMB 803.9 million, primarily reflecting payments from MSD. This financial performance underscores the company’s growing presence in the global pharmaceutical market and its strategic partnerships.-Fineline Info & Tech
